The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
Matthew H G Katz - One of the best experts on this subject based on the ideXlab platform.
-
long term survival after multidisciplinary management of resected pancreatic adenocarcinoma
Annals of Surgical Oncology, 2009Co-Authors: Matthew H G Katz, Huamin Wang, Jason B Fleming, Charlotte C Sun, Rosa F Hwang, Robert A Wolff, Gauri R Varadhachary, James L Abbruzzese, Christopher H CraneAbstract:Introduction Actual 5-year survival rates of 10–18% have been reported for patients with resected pancreatic adenocarcinoma (PC), but the use of Multimodality therapy was uncommon in these series. We evaluated long-term survival and patterns of recurrence in patients treated for PC with contemporary staging and Multimodality therapy.
Bradford J Wood - One of the best experts on this subject based on the ideXlab platform.
-
Multimodality image fusion guided procedures technique accuracy and applications
CardioVascular and Interventional Radiology, 2012Co-Authors: Nadine Abijaoudeh, Jochen Kruecker, Samuel Kadoury, Hicham Kobeiter, Aradhana M Venkatesan, Elliot Levy, Bradford J WoodAbstract:Personalized therapies play an increasingly critical role in cancer care: Image guidance with Multimodality image fusion facilitates the targeting of specific tissue for tissue characterization and plays a role in drug discovery and optimization of tailored therapies. Positron-emission tomography (PET), magnetic resonance imaging (MRI), and contrast-enhanced computed tomography (CT) may offer additional information not otherwise available to the operator during minimally invasive image-guided procedures, such as biopsy and ablation. With use of Multimodality image fusion for image-guided interventions, navigation with advanced modalities does not require the physical presence of the PET, MRI, or CT imaging system. Several commercially available methods of image-fusion and device navigation are reviewed along with an explanation of common tracking hardware and software. An overview of current clinical applications for Multimodality navigation is provided.
Christopher H Crane - One of the best experts on this subject based on the ideXlab platform.
-
long term survival after multidisciplinary management of resected pancreatic adenocarcinoma
Annals of Surgical Oncology, 2009Co-Authors: Matthew H G Katz, Huamin Wang, Jason B Fleming, Charlotte C Sun, Rosa F Hwang, Robert A Wolff, Gauri R Varadhachary, James L Abbruzzese, Christopher H CraneAbstract:Introduction Actual 5-year survival rates of 10–18% have been reported for patients with resected pancreatic adenocarcinoma (PC), but the use of Multimodality therapy was uncommon in these series. We evaluated long-term survival and patterns of recurrence in patients treated for PC with contemporary staging and Multimodality therapy.
Janice L Pasieka - One of the best experts on this subject based on the ideXlab platform.
-
anaplastic thyroid cancer and primary thyroid lymphoma a review of these rare thyroid malignancies
Journal of Surgical Oncology, 2006Co-Authors: Lawrence D Green, Lloyd A Mack, Janice L PasiekaAbstract:Background To review the current literature on the treatment of anaplastic thyroid cancer (ATC) and thyroid lymphoma (TL). Results Both anaplastic carcinoma (ATC) and TL represent rare forms of thyroid cancer. ATC behaves in a highly aggressive manner, resulting in significant morbidity and mortality. Multimodality therapy consisting of both radiotherapy (RT) and chemotherapy is essential in obtaining local/regional control. Although ATC has been relatively chemo resistant, newer agents such like taxotere show promise. The role of surgery in the treatment of ATC continues to evolve, presently it should be reserved for patients who have shown an initial response to Multimodality therapy and in patients in whom a complete macroscopic resection can be achieved with minimal morbidity. The successful treatment of TL currently lies in accurately diagnosing the histological subtype. Both large B-cell and mixed lymphomas are best treated with Multimodality therapy consisting of CHOP combined with hyper-fractioned RT. MALT lymphomas with there more indolent course may be amenable to single modality RT or total thyroidectomy if diagnosed at an early stage IE. Discussion Although both ATC and TL are rare, it is important for surgeons to be aware of the need for Multimodality therapy when treating these patients and to understand the limited role surgery plays in diagnosis and treatment. J. Surg. Oncol. 2006;94:725–736. © 2006 Wiley-Liss, Inc.
John T Wulu - One of the best experts on this subject based on the ideXlab platform.
-
iliofemoral deep vein thrombosis conventional therapy versus lysis and percutaneous transluminal angioplasty and stenting
Annals of Surgery, 2001Co-Authors: Ali F Aburahma, Samuel E Perkins, John T WuluAbstract:Objective To compare conventional treatment (heparin and warfarin) of iliofemoral venous thrombosis with Multimodality treatment (lysis and stenting). Background Data Several studies have reported on conventional therapy for iliofemoral venous thrombosis with disappointing results. However, more recent studies have reported better results with Multimodality treatment. Methods Fifty-one consecutive patients with extensive iliofemoral venous thrombosis were treated during a 10-year period. If there were no contraindications, patients were given the option to choose between conventional therapy (group 1 ) and Multimodality therapy (group 2). The Multimodality treatment strategy included catheter-directed lysis followed by percutaneous transluminal balloon angioplasty (PTA) and stenting for residual iliac stenoses. All patients underwent routine venous duplex imaging at 30 days, 3 months, 6 months, and every 6 months thereafter. Results There were 33 patients in group 1 and 18 patients in group 2. Demographic and clinical characteristics were comparable for both groups. Initial lysis was achieved in 16 of 18 patients (89%) in group 2. Ten of 18 patients in group 2 had residual stenosis after lysis (8 primary and 2 secondary to malignancy), and they were treated with PTA/stenting with an initial success rate of 90%. Two patients in group 1 (6%) had a symptomatic pulmonary embolism (none in group 2). At 30 days, venous patency and symptom resolution were achieved in 1 of 33 patients (3%) in group 1 versus 15 of 18 (83%) in group 2. Kaplan-Meier analysis showed primary iliofemoral venous patency rates at 1, 3, and 5 years of 24%, 18%, and 18% and 83%, 69%, and 69% for groups 1 and 2, respectively. Long-term symptom resolution was achieved in 10 of 33 patients (30%) in group 1 versus 14 of 18 (78%) in group 2. Kaplan-Meier life table analysis showed similar survival rates at 1, 3, and 5 years of 100%, 93%, and 85% for group 1 and 100%, 93%, and 81% for group 2. Conclusions Lysis/stenting treatment was more effective than conventional treatment in patients with iliofemoral vein thrombosis.
